Arbutus Biopharma Corp Q3 2024 Earnings Call Highlights Promising Clinical Trials and ...
| ABUS Stock | USD 3.47 0.06 1.76% |
Slightly above 53% of Arbutus Biopharma's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Arbutus Biopharma Corp suggests that some traders are interested. Arbutus Biopharma's investing sentiment can be driven by a variety of factors including economic data, Arbutus Biopharma's earnings reports, geopolitical events, and overall market trends.
Arbutus |
Cash, Cash Equivalents, and Investments Approximately 131 million as of the end of Q3 2024.Cash Burn Expected to range from 63 million to 67 million for 2
Read at gurufocus.com
 |
Arbutus Biopharma Fundamental Analysis
We analyze Arbutus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Arbutus Biopharma is currently under evaluation in target price category among its peers.
Arbutus Biopharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arbutus Biopharma stock to make a market-neutral strategy. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics with similar companies.
Peers
Arbutus Biopharma Related Equities
| CRVS | Corvus Pharmaceuticals | 7.90 | ||||
| ADAP | Adaptimmune Therapeutics | 7.35 | ||||
| ADMA | ADMA Biologics | 0.05 | ||||
| AFMD | Affimed NV | 1.05 |
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.